Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...

Google’s artificial intelligence arm DeepMind has been holding back the release of its world-renowned research, as it seeks ...

Isomorphic Labs was founded to apply artificial intelligence to drug discovery. The company is led by AI researcher Sir Demis Hassabis.

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

Investing.com-- Google’s (NASDAQ: GOOGL) artificial intelligence research arm, DeepMind, has imposed stricter controls on the ...

Google’s AI arm led by Demis Hassabis makes it harder for its researchers to publish studies in major change in approach ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Dr David Baker's Nobel Prize-winning breakthrough of designing new proteins has the potential to stop cancers, pandemics, fix ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...